Response to 'Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study'

  • Kazuki Yoshida1Email author,

    Affiliated with

    • Kazuo Matsui1,

      Affiliated with

      • Hiroto Nakano1,

        Affiliated with

        • Hideto Oshikawa1,

          Affiliated with

          • Masako Utsunomiya1,

            Affiliated with

            • Tatsuo Kobayashi1,

              Affiliated with

              • Makiko Kimura1,

                Affiliated with

                • Gautam A Deshpande2 and

                  Affiliated with

                  • Mitsumasa Kishimoto3

                    Affiliated with

                    Arthritis Research & Therapy201113:405

                    DOI: 10.1186/ar3393

                    Published: 18 August 2011

                    We read with interest the report by Lee and colleagues in the June issue of Arthritis Research & Therapy [1]. The study compared the Disease Activity Score in 28 joints calculated by using C-reactive protein (DAS28-CRP) versus American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission in terms of residual pain. The authors stated that DAS28-CRP remission criteria allowed for persistence of pain in more than 10% of patients, whereas there were very few complaints of pain among patients in ACR/EULAR remission. This is a very important finding as it clearly demonstrated incompetence of the DAS28-CRP remission criteria in defining remission that is meaningful for patients, thus encouraging transition to new ACR/EULAR remission criteria.

                    One factor, however, that was not mentioned in the article and which may be of interest is the Disease Activity Score in 28 joints calculated by using erythrocyte sedimentation rate (DAS28-ESR). Although the DAS28-CRP is a validated score demonstrating good correlation with the DAS28-ESR [2], the DAS28-CRP frequently results in lower scores than its erythrocyte sedimentation rate counterpart [2, 3]. Inoue and colleagues thus suggested a different cut-off point of 2.3 for the DAS28-CRP [3]. This tendency was also demonstrated in our cohort of 265 rheumatoid arthritis patients taking biologics (Figure 1). When plotted against the DAS28-ESR, the DAS28-CRP resulted in lower values (below the diagonal line, indicating complete agreement) more often than not. Also noteworthy is that the DAS28-CRP is never lower than 0.96, which is the constant term in the following equation [4]:
                    http://static-content.springer.com/image/art%3A10.1186%2Far3393/MediaObjects/13075_2011_3145_Fig1_HTML.jpg
                    Figure 1

                    Relationship between the Disease Activity Scores in 28 joints calculated by using C-reactive protein and erythrocyte sedimentation rate. Relationship between the Disease Activity Score in 28 joints calculated by using C-reactive protein (DAS28-CRP) and the Disease Activity Score in 28 joints calculated by using erythrocyte sedimentation rate (DAS28-ESR) in our biologic cohort.

                    http://static-content.springer.com/image/art%3A10.1186%2Far3393/MediaObjects/13075_2011_3145_Equa_HTML.gif

                    in which TJC stands for tender joint count, SJC for swollen joint count, ln for natural logarithm, CRP for C-reactive protein, and GH for global health as reported by the patient.

                    We therefore wonder whether Lee and colleagues performed the same analysis with DAS28-ESR remission criteria. We think it may be interesting to perform the same analysis with DAS28-ESR remission criteria or a stricter DAS28-CRP cut-off point of 2.3.

                    Abbreviations

                    ACR/EULAR: 

                    American College of Rheumatology/European League Against Rheumatism

                    DAS28-CRP: 

                    Disease Activity Score in 28 joints calculated by using C-reactive protein

                    DAS28-ESR: 

                    Disease Activity Score in 28 joints calculated by using erythrocyte sedimentation rate.

                    Declarations

                    Authors’ Affiliations

                    (1)
                    Department of Rheumatology, Kameda Medical Center
                    (2)
                    Center for Clinical Epidemiology, St. Luke’s International Hospital
                    (3)
                    Division of Allergy and Rheumatology, St. Luke’s International Hospital

                    References

                    1. Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME, Solomon DH: Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011, 13:R83.PubMedView Article
                    2. Wells G, Becker J-C, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PLCM: Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009, 68:954–960.PubMedView Article
                    3. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N: Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007, 66:407–409.PubMedView Article
                    4. DAS-SCORE.NL: Home of the DAS [http://​www.​das-score.​nl/​]

                    Copyright

                    © BioMed Central Ltd 2011

                    Advertisement